ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child‐Turcotte‐Pugh score and the Model for End‐Stage Liver Disease score

Takaya, Hiroaki; Uemura, Mamoru; Fujimura, Yoshihiro; Matsumoto, Masanori; Matsuyama, Toyoki; Kato, Seiji; Morioka, Chie; Ishizashi, Hiromichi; Hori, Yuji; Fujimoto, Masao; Tsujimoto, Tatsuhiro; Kawaratani, Hideto; Toyohara, Masahisa; Kurumatani, Norio; Fukui, Hiroshi

doi:10.1111/j.1872-034x.2011.00950.x

Cited by 45 publications

(54 citation statements)

References 56 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A decline in ADAMTS13 levels with increasing severity of liver disease also promotes normal platelet function. 14 Fibrinolysis is also rebalanced in chronic liver disease due to parallel changes in profibrinolytic and antifibrinolytic proteins.…”

Section: Rebalanced Hemostasismentioning

confidence: 99%

Coagulopathy in liver disease: a balancing act

2015

View full text Add to dashboard Cite

Liver disease results in complex alterations of all 3 phases of hemostasis. It is now recognized that hemostasis is rebalanced in chronic liver disease. The fall in clotting factor levels is accompanied by a parallel fall in anticoagulant proteins. High von Willebrand factor levels counteract defects in primary hemostasis. Conventional coagulation tests do not fully reflect the derangement in hemostasis and do not accurately predict the risk of bleeding. Global coagulation assays (thrombin generation, thromboelastography) reflect the interaction between procoagulant factors, anticoagulant factors, platelets, and the fibrinolytic system and show promise for assessing bleeding risk and guiding therapy. These assays are not yet commercially approved or validated. Prevention of bleeding should not be aimed at correcting conventional coagulation tests. Thrombopoietin receptor agonists were shown to increase the platelet count in cirrhotic patients undergoing invasive procedures

show abstract

Section: Rebalanced Hemostasismentioning

confidence: 99%

Coagulopathy in liver disease: a balancing act

2015

View full text Add to dashboard Cite

show abstract

“…This is particularly true for the vitamin K-dependent procoagulant factors II, VII, IX, and X, as well as for factor V, but also for the vitamin K-dependent anticoagulant factors protein C and protein S, as well as for antithrombin [1 && ]. A marked imbalance between decreased ADAMTS13 activity and increased production of large vWF multimers has been shown to be closely related to functional liver capacity, hepatic encephalopathy, hepatorenal syndrome, and intractable ascites in advanced liver cirrhosis and may be useful to predict long-term survival of cirrhotic patients [3,4]. On the other hand, the activity of the vWF cleaving enzyme ADAMTS13, a metalloprotease exclusively produced in hepatic stellate cells, is reduced in liver cirrhotic patients.…”

Section: Coagulopathy In Liver Dysfunctionmentioning

confidence: 99%

Coagulation pattern in critical liver dysfunction

Schaden

Saner²,

Goerlinger³

2013

Current Opinion in Critical Care

View full text Add to dashboard Cite

show abstract

“…Several previous studies have, however, reported conflicting data on a potential functional role of ADAMTS13 in the pathogenesis of liver diseases [reviewed in (12)]. A beneficial effect of ADAMTS13 activity was observed on liver disease severity, and increased ADAMTS13 activity was associated with an improved prognosis of liver cirrhosis (13), alcoholic hepatitis (14) and hepatic veno-occlusive disease (15). In contrast, a detrimental effect of ADAMTS13 was reported on hepatocellular carcinoma risk in patients suffering from chronic liver disease (16).…”

Section: Introductionmentioning

confidence: 99%

Role of ADAMTS13 in diet-induced liver steatosis

Geys

Roose

Vanhoorelbeke

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Previous studies, predominantly based on increased or decreased plasma levels, have reported conflicting data on a potential functional role of ADAMTS13 in the pathogenesis of liver diseases, including non‑alcoholic steatohepatitis (NASH). The aim of the current study was to evaluate whether ADAMTS13 deficiency affects development of NASH. Therefore, male wild‑type (WT) and Adamts13 deficient (Adamts13‑/‑) mice were kept on a steatosis‑inducing diet devoid of methionine and choline (MCD) or a control diet (MCC) for 4 weeks. Induction of NASH did not affect plasma ADAMTS13 antigen levels of WT mice. MCD as compared with MCC feeding resulted in reduced body and liver weight with no differences between the genotypes. Plasma levels of the liver enzymes AST and ALT were significantly higher for MCD vs. MCC fed Adamts13‑/‑ and WT mice, however were not different between the genotypes. Liver triglyceride levels were also higher after MCD feeding, but were not different between WT and Adamts13‑/‑ mice. Adamts13‑/‑ mice on the two diets exhibited higher insulin sensitivity when compared with WT mice. On the MCC diet, the genotype did not show clear histological abnormalities in the liver, whereas severe steatosis and fibrosis were observed on MCD diet, however were comparable for both genotypes. This was supported by comparably enhanced hepatic expression in the two genotypes on MCD diet of the steatosis marker CD36 and of the fibrosis marker tissue inhibitor of metalloproteinase 1. Thus, the results of the current study do not support a functional role of ADAMTS13 in this murine model of NASH.

show abstract

ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child‐Turcotte‐Pugh score and the Model for End‐Stage Liver Disease score

Cited by 45 publications

References 56 publications

Coagulopathy in liver disease: a balancing act

Coagulopathy in liver disease: a balancing act

Coagulation pattern in critical liver dysfunction

Role of ADAMTS13 in diet-induced liver steatosis

Contact Info

Product

Resources

About